Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its third-quarter financial results on November 12, 2026, after U.S. financial markets close.

Rhea-AI Summary

Nektar Therapeutics (Nasdaq: NKTR) will announce its third-quarter financial results on November 12, 2026, after U.S. financial markets close. The results cover the quarter ended September 30, 2026. President and CEO Howard Robin will host a conference call at 5:00 p.m. Eastern Time. A live audio webcast will be available through the company's investor website, with replay access through December 12, 2026.

Key Figures

Results announcement date: November 12, 2026

Results announcement date

November 12, 2026

Q3 2026 financial results scheduled after market close

Key Terms

regulatory t cell, bispecific, hematopoietic colony stimulating factor

3 terms

regulatory t cell medical

"a novel, first-in-class regulatory T cell stimulator"

Regulatory T cells are a type of immune cell that act like peacekeepers, calming other immune cells to prevent excessive or misdirected attacks on the body. For investors, they matter because therapies that boost or block these cells can treat autoimmune diseases, transplant rejection, or cancer, making them a focal point for drug development and a potential driver of company value if therapies prove safe and effective.

bispecific medical

"preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs"

A bispecific molecule is a therapeutic designed to bind two different biological targets at once — imagine a two-headed key that fits two locks simultaneously. For investors, bispecific therapies matter because that dual-action can make a treatment more effective or selective, potentially improving clinical results, altering safety profiles, and creating a stronger commercial edge; those factors directly affect development risk, regulatory chances, and future revenue prospects.

hematopoietic colony stimulating factor medical

"a modified hematopoietic colony stimulating factor (CSF) protein"

A hematopoietic colony-stimulating factor is a naturally occurring or manufactured protein that stimulates the growth, survival and differentiation of blood-forming progenitor cells in the bone marrow so they form colonies of specific blood cell types (for example neutrophils or red cells). These factors act by binding receptors on hematopoietic progenitor cells and promoting proliferation and maturation; they affect precursor cells rather than directly increasing numbers of fully mature blood cells. They may be produced by the body or given as recombinant drugs to accelerate recovery of particular blood cell lines after chemotherapy, bone marrow suppression or certain medical procedures, and their use can be associated with predictable effects on blood counts and known side effects related to marrow stimulation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Oct. 27, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through December 12, 2026.

To access the conference call, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus. Nektar's pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contacts

For Investors:

Vivian Wu
628-895-0661
VWu@nektar.com 

Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com 

For Media:

Susan Roberts
LifeSci Communications
202-779-0929
sroberts@lifescicomms.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-announce-financial-results-for-the-third-quarter-on-thursday-november-12-2026-after-close-of-us-based-financial-markets-302921182.html

SOURCE Nektar Therapeutics